Zentiva K.s.

Sanofi

Ondrej Dammer

Jindrich Richter

Pascal Billot

Ludek Ridvan

Josef Hajicek

Tomas Pekarek

Kamal Jarrah

Eszter Tieger

Lukas Krejcik

Norbert Nagel

Jan Stach

Michal Voslar

Petr Lehnert

Josef Zezula

Jaroslava Svobodova

Gary James Miller

Petr Mikes

Stephanie Greco

Tomas Chvojka

Ales Halama

Marcela Tkadlecova

Alena Prokopova

Peter Babiak

Tomas Gurgut

Winfried Heyse

Hana Tozickova

Violetta Kiss

Igor Cerna

Pavel Zvatora

Michal Zapadlo

Pavel Hanzlik

Daniel Pribyl

Jan Linek

Monika Kofrankova

Jan Holan

Lionel Bardet

Cyrus Victor Skaria

Jean Rene Authelin

Pavla Chalupova

Patrik Hosek

Amandine Mathieu

Anna Hanovska

Aleksandra Dumicic

Mokhtar Kebbati

Mostafa Nakach

Jaroslav Rezac

Vladimír KRÁL

Josef Beranek

The invention relates to a pharmaceutical composition comprising the active ingredients rosuvastatin of formula I, with the systematic name (3R,5S,6E)-7-[4-(4-fluorophenyl)-2-(N-methylmethanesulfonamido)-6-(propan-2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid or its pharmaceutically acceptable salts, esters, hydrates or solvates, and ezetimibe of formula II, with the systematic name (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one or its pharmaceutically acceptable salts, esters, hydrates or solvates, as well as a preparation method of this pharmaceutical composition. The weight ratio of the layers is 1:2 to 2:1.

Pharmaceutical composition comprising rosuvastatin and ezetimibe and a preparation method thereof

The compounds are crystalline modifications of methyl (3Z)-3-{[4-{methyl[(4-methylpiperazin-1-yl)acetyl]amino}phenyl)amino](phenyl)methylidene}-2-oxo-2,3-dihydro-1H-indole-6-carboxylate salts of Formula I, wherein H&#x2014;X represents at least one acid component, processes for the preparation thereof, and pharmaceutical compositions. 

Crystalline modifications of methyl (3Z)-3-{[(4-{methyl[(4-methylpiperazin-1-yl)acetyl]amino}phenyl)amino](phenyl)methylidene}-2-oxo-2,3-dihydro-1H-indole-6-carboxylate salts and methods of preparation thereof

The invention relates to a new crystalline form of Canagliflozin of formula I, with its systematic name (2S,3R,4R,5S,6R)-2-(3-((5-(4-fluorophenyl)thiophen-2-yl) methyl)-4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol5 and a method of its preparation.

Crystalline form of Canagliflozin and a method of its preparation

A stable polymorph (Form Z1) of the salt of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro [152,4]triazolo[4,3-&#x3b1;]pyrazin-7(8H)-yl]-1-(2s4,5-trifluorophenyl)butan-2-amine (sitagliptin) with L-tartaric acid, of formula 1, which is a very suitable form of the active pharmaceutical ingredient of medicinal products intended especially for treatment of diabetes type 2. A method of preparation of the stable polymorph (Form Z1) of the salt of sitagliptin with L-tartaric acid, as well as its use for the preparation of a pharmaceutical composition. 

Stable polymorph of the salt of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-&#x3b1;]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-anime with L-tartaric acid

The present invention relates to novel solid forms of agomelatine (I), specifically novel phaamaceutically acceptable cocrystals thereof, as well as to methods of preparing them. Three pharmaceutically acceptable cocrystals of (I) that have physico-chemical properties acceptable for pharmaceutical development were obtained. 

Pharmaceutically acceptable cocrystals of N-[2-(7-methoxyl-1-naphtyl)ethyl]acetamide and methods of their preparation

Growing community of inventors

Hostivice, Czechia

Ondrej Dammer